MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 464410 | Name: Cilnidipine-d7
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cilnidipine-d7 is intended for use as an internal standard for the quantification of cilnidipine by GC- or LC-MS. Cilnidipine is a dihydropyridine calcium channel blocker that blocks L- and N-type high-voltage-activated calcium currents in rat hippocampal CA1 pyramidal neurons when used at a concentration of 10 μM. Cilnidipine (3 mg/kg) reduces the pressor response to acute cold stress, as well as mean blood pressure, in spontaneously hypertensive rats. It dose-dependently reduces mean blood pressure and cerebral vascular resistance without affecting cerebral blood flow in anesthetized rats at doses ranging from 3-100 μg/kg. Cilnidipine (100 μg/kg, i.p.) reduces cerebral infarction area in a rat model of focal brain ischemia.

Chemical Structure

Cilnidipine-d7
Cilnidipine-d7
CAS#Cilnidipine-d7

Theoretical Analysis

MedKoo Cat#: 464410

Name: Cilnidipine-d7

CAS#: Cilnidipine-d7

Chemical Formula: C27H21D7N2O7

Exact Mass: 499.2336

Molecular Weight: 499.57

Elemental Analysis: C, 64.92; H, 7.06; N, 5.61; O, 22.42

Price and Availability

Size Price Availability Quantity
1mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Cilnidipine-d7 132203-70-4
Synonym
Cilnidipine-d7; Cilnidipine d7;
IUPAC/Chemical Name
3-cinnamyl 5-(2-(methoxy-d3)ethyl-1,1,2,2-d4) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key
KJEBULYHNRNJTE-UPZNXPSBSA-N
InChi Code
InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+/i3D3,15D2,16D2
SMILES Code
O=C(OC/C=C/C1=CC=CC=C1)C2=C(NC(C)=C(C2C3=CC([N+]([O-])=O)=CC=C3)C(OC([2H])(C([2H])(OC([2H])([2H])[2H])[2H])[2H])=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 499.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yamashita T, Kamikaseda S, Tanaka A, Tozaki-Saitoh H, Caaveiro JMM, Inoue K, Tsuda M. New Inhibitory Effects of Cilnidipine on Microglial P2X7 Receptors and IL-1β Release: An Involvement in its Alleviating Effect on Neuropathic Pain. Cells. 2021 Feb 18;10(2):434. doi: 10.3390/cells10020434. PMID: 33670748; PMCID: PMC7922706. 2: Harada E, Sugino K, Aimoto M, Takahara A. Effects of the L/N-type Ca2+ Channel Blocker Cilnidipine on the Cardiac Histological Remodelling and Inducibility of Atrial Fibrillation in High-salt-fed Rats. Biol Pharm Bull. 2021 Feb 27. doi: 10.1248/bpb.b21-00024. Epub ahead of print. PMID: 33642455. 3: Harlalka S , Roy UK , Majumdar G , Das K , Mandal P . An Open Label Prospective Study on Evaluation of Safety and Efficacy of Cilnidipine Over Amlodipine in Stage 1 Hypertensive Patients. Kathmandu Univ Med J (KUMJ). 2020 Jan.-Mar;18(69):42-48. PMID: 33582687. 4: Shimizu K, Imamura H, Tani S, Adachi H, Sakai C, Ishii A, Kataoka H, Miyamoto S, Aoki T, Sakai N. Candidate drugs for preventive treatment of unruptured intracranial aneurysms: A cross-sectional study. PLoS One. 2021 Feb 12;16(2):e0246865. doi: 10.1371/journal.pone.0246865. PMID: 33577580; PMCID: PMC7880482. 5: Karemore MN, Bali NR. Gellan gum based gastroretentive tablets for bioavailability enhancement of cilnidipine in human volunteers. Int J Biol Macromol. 2021 Mar 31;174:424-439. doi: 10.1016/j.ijbiomac.2021.01.199. Epub 2021 Feb 1. PMID: 33539955. 6: Fujiwara T, Hoshide S, Tomitani N, Kanegae H, Kario K. Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure. J Clin Hypertens (Greenwich). 2021 Mar;23(3):687-691. doi: 10.1111/jch.14199. Epub 2021 Jan 26. PMID: 33497537. 7: Kawabata Y, Soeki T, Ito H, Matsuura T, Kusunose K, Ise T, Yamaguchi K, Tobiume T, Yagi S, Fukuda D, Yamada H, Wakatsuki T, Kitani M, Kawano K, Taketani Y, Sata M. Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients. Int J Hypertens. 2020 Dec 22;2020:6653851. doi: 10.1155/2020/6653851. PMID: 33489354; PMCID: PMC7803135. 8: Kario K, Matsuda S, Nagahama S, Kurose Y, Sugii H, Teshima T, Suzuki N. Single-pill combination of cilnidipine, an l-/n-type calcium channel blocker, and valsartan reduces the day-by-day variability of morning home systolic blood pressure in patients with treated hypertension: A sub-analysis of the HOPE-combi survey. J Clin Hypertens (Greenwich). 2021 Feb;23(2):392-397. doi: 10.1111/jch.14178. Epub 2021 Jan 17. PMID: 33455076. 9: Diwan R, Ravi PR, Agarwal SI, Aggarwal V. Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. Pharm Dev Technol. 2021 Mar;26(3):278-290. doi: 10.1080/10837450.2020.1864643. Epub 2021 Jan 6. PMID: 33319618. 10: Bagali S, Nerune SM, Reddy RC, Yendigeri SM, Patil BS, Naikwadi AA, Kulkarni RV, Das KK. Low oxygen microenvironment and cardiovascular remodeling: Role of dual L/N.type Ca2+ channel blocker. Indian J Pharmacol. 2020 Sep- Oct;52(5):383-391. doi: 10.4103/ijp.IJP_136_20. PMID: 33283770. 11: Liang H, Hu H, Shan D, Lyu J, Yan X, Wang Y, Jian F, Li X, Lai W, Long H. CGRP Modulates Orofacial Pain through Mediating Neuron-Glia Crosstalk. J Dent Res. 2021 Jan;100(1):98-105. doi: 10.1177/0022034520950296. Epub 2020 Aug 27. PMID: 32853530. 12: Shiraki A, Nakashima K, Node K. Does cilnidipine, a dual L- and N-type Ca2+ blocker, shows promise in drug repositioning approaches? Hypertens Res. 2020 Jul;43(7):726-728. doi: 10.1038/s41440-020-0452-y. Epub 2020 May 12. PMID: 32398796. 13: Diwan R, Ravi PR, Pathare NS, Aggarwal V. Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of design of experiments. Colloids Surf B Biointerfaces. 2020 Sep;193:111073. doi: 10.1016/j.colsurfb.2020.111073. Epub 2020 Apr 24. PMID: 32388122. 14: Diwan R, Khan S, Ravi PR. Comparative study of cilnidipine loaded PLGA nanoparticles: process optimization by DoE, physico-chemical characterization and in vivo evaluation. Drug Deliv Transl Res. 2020 Oct;10(5):1442-1458. doi: 10.1007/s13346-020-00732-5. PMID: 32329025. 15: Naseratun N, Kobara M, Watanabe Y, Toba H, Nakata T. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2020 Sep;47(9):1545-1553. doi: 10.1111/1440-1681.13329. Epub 2020 May 25. PMID: 32323339. 16: Kario K, Matsuda S, Nagahama S, Kurose Y, Sugii H, Teshima T, Suzuki N. Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey. J Clin Hypertens (Greenwich). 2020 Mar;22(3):457-464. doi: 10.1111/jch.13771. PMID: 32311215. 17: Chaudhari SR, Shirkhedkar AA. An Investigative Review for Pharmaceutical Analysis of 1,4-Dihydropyridine-3,5-Dicarboxylic Acid Derivative: Cilnidipine. Crit Rev Anal Chem. 2020 Feb 12:1-10. doi: 10.1080/10408347.2020.1718483. Epub ahead of print. PMID: 32048875. 18: Matsuda S, Nagahama S, Kurose Y, Wakabayashi M, Sugii H, Teshima T, Suzuki N, Kario K. A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations. Clin Exp Hypertens. 2020 Aug 17;42(6):502-511. doi: 10.1080/10641963.2020.1714641. Epub 2020 Jan 22. PMID: 31964180. 19: Minato H, Hisatome I, Kurata Y, Notsu T, Nakasone N, Ninomiya H, Hamada T, Tomomori T, Okamura A, Miake J, Tsuneto M, Shirayoshi Y, Endo R, Otsuki A, Okada F, Inagaki Y. Pretreatment with cilnidipine attenuates hypoxia/reoxygenation injury in HL-1 cardiomyocytes through enhanced NO production and action potential shortening. Hypertens Res. 2020 May;43(5):380-388. doi: 10.1038/s41440-019-0391-7. Epub 2020 Jan 15. PMID: 31942044. 20: Yokoyama K, Minami T, Seki M, Okada Y, Kumagai H, Yamagata T. A boy with Alagille syndrome coexisting with mid-aortic syndrome and renovascular hypertension. J Cardiol Cases. 2019 Sep 27;21(1):28-31. doi: 10.1016/j.jccase.2019.09.010. PMID: 31933703; PMCID: PMC6951447.